Aripiprazole inhibits superoxide generation from phorbol-myristate-acetate (PMA)-stimulated microglia in vitro: implication for antioxidative psychotropic actions via microglia
Related Experiment Video
Updated: Jun 2, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Takahiro A Kato1, Akira Monji, Keiji Yasukawa
1Department of Neuropsychiatry, Graduate School of Medical Sciences, Kyushu University, Maidashi 3-1-1, Fukuoka 812-8582, Japan. takahiro@npsych.med.kyushu-u.ac.jp
Abstract:
Altered antioxidant status has been implicated in schizophrenia. Microglia, major sources of free radicals such as superoxide (•O(2)(-)), play crucial roles in various brain pathologies. Recent postmortem and imaging studies have indicated microglial activation in the brain of schizophrenic patients. We previously demonstrated that atypical antipsychotics including aripiprazole significantly inhibited the release of nitric oxide and proinflammatory cytokines from interferon-γ-stimulated microglia in vitro. Antioxidative effects of antipsychotics via modulating microglial superoxide generation have never been reported. Therefore, we herein investigated the effects of antipsychotics on the •O(2)(-) generation from phorbol-myristate-acetate (PMA)-stimulated rodent microglia by the electron spin resonance (ESR) spectroscopy and also examined the intracellular mechanism by intracellular Ca(2+) imaging and immunostaining. Neuronal damage induced by microglial activation was also investigated by the co-culture experiment. Among various antipsychotics, only aripiprazole inhibited the •O(2)(-) generation from PMA-stimulated microglia. Aripiprazole proved to inhibit the •O(2)(-) generation through the cascade of protein kinase C (PKC) activation, intracellular Ca(2+) regulation and NADPH oxidase activation via cytosolic p47(phox) translocation to the plasma/phagosomal membranes. Formation of neuritic beading, induced by PMA-stimulated microglia, was attenuated by pretreatment of aripiprazole. D2R antagonism has long been considered as the primary therapeutic action for schizophrenia. Aripiprazole with D2R partial agonism is effective like other antipsychotics with fewer side effects, while aripiprazole's therapeutic mechanism itself remains unclear. Our results imply that aripiprazole may have psychotropic effects by reducing the microglial oxidative reactions and following neuronal reactions, which puts forward a novel therapeutic hypothesis in schizophrenia research.
Insights
Aripiprazole, an atypical antipsychotic, reduces superoxide generation in activated microglia, a key factor in schizophrenia. This antioxidant effect may explain its therapeutic benefits by protecting neurons from oxidative damage.
Area of Science:
- Neuroscience
- Psychiatry
- Cell Biology
Background:
- Schizophrenia is linked to altered antioxidant status and microglial activation.
- Microglia produce superoxide (•O(2)(-)), a free radical implicated in brain pathologies.
- Atypical antipsychotics, like aripiprazole, may influence microglial activity.
Purpose of the Study:
- To investigate the antioxidative effects of antipsychotics on microglial superoxide generation.
- To elucidate the intracellular mechanisms underlying aripiprazole's effects on microglia.
- To examine the impact of aripiprazole on microglial-induced neuronal damage.
Main Methods:
- Electron spin resonance (ESR) spectroscopy to measure superoxide generation in phorbol-myristate-acetate (PMA)-stimulated microglia.
- Intracellular Ca(2+) imaging and immunostaining to analyze intracellular mechanisms.
- Co-culture experiments to assess microglial-induced neuronal damage.
Main Results:
- Aripiprazole significantly inhibited superoxide generation in PMA-stimulated microglia.
- Aripiprazole's inhibitory effect involved protein kinase C (PKC) activation, Ca(2+) regulation, and NADPH oxidase activation.
- Aripiprazole pretreatment attenuated neuritic beading, a marker of neuronal damage induced by activated microglia.
Conclusions:
- Aripiprazole exhibits antioxidative effects by reducing microglial superoxide production.
- This mechanism, involving modulation of oxidative stress and neuronal protection, offers a novel therapeutic hypothesis for schizophrenia.
- Aripiprazole's unique D2 receptor partial agonism may contribute to its efficacy through these neuroprotective pathways.
Related Concept Videos
Drugs Affecting Neurotransmitter Synthesis
Antidepressant Drugs: MAOIs and Other Agents
